At ASCO GI 2025, Thierry André and colleagues presented CheckMate 8HW results, showing nivolumab (NIVO) + ipilimumab (IPI) outperforms NIVO alone in MSI-H/dMMR metastatic colorectal cancer (mCRC).
Key findings:
✅ PFS significantly improved with NIVO + IPI (HR=0.62, p=0.0003)
✅ Higher ORR: 71% (NIVO + IPI) vs. 58% (NIVO alone), p=0.0011
✅ No new safety concerns
Under Dr. André’s leadership, this study supports NIVO + IPI as a potential new standard for MSI-H/dMMR mCRC. Acknowledgment to Elena Elez, Heinz-Josef Lenz, Eric Van Cutsem, Takayuki Yoshino, and the research team for their contributions.
Read more: https://lnkd.in/ejHMDsUr
